Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
43pct
1d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
Verifying Accurate Leading-edge IVCT Development Act of 2021 or the VALID Act of 2021 This bill requires the Food and Drug Administration (FDA) to regulate in vitro clinical tests (IVCTs). Currently, the FDA and the Centers for Medicare & Medicaid Services have authority to regulate in vitro diagnostic devices. The bill defines IVCTs, which includes in vitro diagnostic devices, as tests intended for the collection, preparation, analysis, or in vitro clinical examination of specimens from the human body to provide information about a disease, condition, or treatment. An IVCT may not be introduced into interstate commerce unless it has received FDA premarket approval or is covered by certain exemptions, such as an exemption for a test that (1) was developed and introduced before this bill's enactment and meets certain requirements, (2) is a low-risk test, (3) is solely for public health surveillance, (4) is covered by a technology certification issued under this bill, or (5) has received a humanitarian exemption or emergency use authorization. The FDA may grant upon application a technology certification. Generally, such a certification covers a group of tests that use a single technology and may be evaluated using a representative test. While such a certification is valid, a qualifying IVCT that falls within the scope of the certification shall be cleared for interstate commerce. The bill also imposes various requirements related to IVCTs, including those related to quality control, labeling, and reporting adverse events. The FDA shall have various enforcement authority, including authority to order the recall of an IVCT with a reasonable probability of causing serious adverse health consequences.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (80)
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2024 · fourth_quarter · Health Issues
H.R.4128: VALID Act of 2021. H.R.7213 - Equitable Community Access to Pharmacist Services Act. Issues related to infant formula access.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES
2024 · third_quarter · Health Issues
H.R.4128: VALID Act of 2021. H.R.7213 - Equitable Community Access to Pharmacist Services Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Health Issues
H.R.4128: VALID Act of 2021. H.R.7213 - Equitable Community Access to Pharmacist Services Act. SUPPORT Act reauthorization.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Health Issues
Issues related to UNOS and heart transplant criteria. H.R.4128: VALID Act of 2021. H.R.7213 - Equitable Community Access to Pharmacist Services Act. SUPPORT Act reauthorization.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES
2023 · fourth_quarter · Health Issues
Issues related to UNOS and heart transplant criteria. H.R.4128: VALID Act of 2021. H.R.7213 - Equitable Community Access to Pharmacist Services Act. Reauthorization of PAHPA. SUPPORT Act reauthorization.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES
2023 · third_quarter · Health Issues
H.R.4128 - VALID Act of 2021. Inpatient Prospective Payment System Regulation. ARPA-H BAA/ BARDA DRIVe. Pandemic and All-Hazards Preparedness Act (PAHPA).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · third_quarter · Health Issues
Issues related to UNOS and heart transplant criteria. H.R.4128 - VALID Act of 2021. H.R.7213 - Equitable Community Access to Pharmacist Services Act. Reauthorization of PAHPA. SUPPORT Act reauthorization.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES
2023 · second_quarter · Health Issues
H.R.4128 - VALID Act of 2021. Inpatient Prospective Payment System Regulation. Pandemic and All-Hazards Preparedness Act (PAHPA).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · second_quarter · Health Issues
Drug pricing and access. Implementation of Inflation Reduction Act of 2022. Biosimilars. Pandemic and All-Hazards Preparedness Act (PAHPA). H.R.4128/S.2209 - VALID Act.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
2023 · second_quarter · Medicare/Medicaid
Medicare reimbursement for diagnostics. HR.4128 - VALID Act. Implementation of Inflation Reduction Act of 2022.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · first_quarter · Medical/Disease Research/Clinical Labs
Issues related to regulation of Direct to Consumer (DTC) Genetic Testing, including FDA regulation of DTC tests and privacy in consumer genetics. H.R.4128: VALID Act of 2021. Legislation related to data privacy.
Client expense: Not reported · Firm income: $20,000
2023 · first_quarter · Medical/Disease Research/Clinical Labs
Issues related to regulation of Direct to Consumer (DTC) Genetic Testing, including FDA regulation of DTC tests and privacy in consumer genetics. H.R.4128: VALID Act of 2021. Legislation related to data privacy.
Client expense: Not reported · Firm income: $20,000
2023 · first_quarter · Health Issues
- Issues Related to Data Privacy and Security - Diagnostic and medical device regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209,H.R.4128) and the Verifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348) and the Consolidated Appropriations Act, 2023 (P.L. 117-328) - Cancer Moonshot
Client expense: $100,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2023 · first_quarter · Medicare/Medicaid
Medicare access to diagnostic services. Medicare and Medicaid issues. FDA User Fee. H.R.4128/S.2209 - Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · first_quarter · Health Issues
H.R.4128 - VALID Act of 2021. FDA User Fee Regulations. Inpatient Prospective Payment System Regulation. Pandemic and All-Hazards Preparedness Act (PAHPA).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · first_quarter · Health Issues
Drug pricing and access. Implementation of Inflation Reduction Act of 2022. Biosimilars. Pandemic and All-Hazards Preparedness Act (PAHPA). H.R.4128/S.2209 - VALID Act.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
2023 · first_quarter · Medicare/Medicaid
Medicare reimbursement for diagnostics. HR.4128 - VALID Act. Implementation of Inflation Reduction Act of 2022.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · first_quarter · Health Issues
Issues related to MDUFA implementation Issues related to H.R. 7667, Food and Drug Amendments of 2022 Issues related to S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act Issues relating to FDA Covid-19 Response Issues relating to the medical product supply chain Issues relating to S. 3799, PREVENT Pandemics Act Issues related to CURES 2.0 Issues related to medical device sterilization and the use of ethylene oxide to sterilize medical devices Issues related to the Valid Act of 2021 - H.R. 4128/S.2209 Issues related to cyber security including H.R. 7084/ S. 3983, PATCH Act
Client expense: $300,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · first_quarter · Medical/Disease Research/Clinical Labs
VALID Act of 2021 (H.R.4128/S.2209; Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses; re-introduced in Spring of 2023 as H.R.2639
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Medical/Disease Research/Clinical Labs
HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage S.4348 - FDASLA Act of 2022
Client expense: Not reported · Firm income: $17,500
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Medical/Disease Research/Clinical Labs
HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage S.4348 - FDASLA Act of 2022 FDA Draft Guidance on ctDNA
Client expense: Not reported · Firm income: $90,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Medical/Disease Research/Clinical Labs
HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage S 1666, Verified Innovative Testing in American Laboratories (VITAL) Act S.4348 - FDASLA Act of 2022
Client expense: Not reported · Firm income: $63,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
VALID Act (HR 4128/S.2209); Issues related to proposals on reauthorization of the FDA drug and device user fee programs (S.4348/H.R.7667), (H.R. 6833); Issues related to data privacy and security House legislation (H.R. 8152).
Client expense: $80,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Medical/Disease Research/Clinical Labs
Access and reimbursement to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing;The VALID Act (HR 4128 and S 2209). Increasing overall access to and diversity of clinical trials. Advancing acceptance of Real World Data and Real World Evidence.
Client expense: $80,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Consumer Issues/Safety/Products
H.R. 963/ S. 505, Forced Arbitration Injustice Repeal Act (FAIR). H.R. 2195, Protecting the Employment Rights of Service Members Act (PERSA). H.R. 2196, Justice for Servicemembers Act. H.R. 2812, Fairness in Nursing Home Arbitration Act. H.R. 3947, bill to prohibit forced arbitration in health insurance contracts. S. 1334, PFAS Accountability Act. H.R. 2467, PFAS Action Act of 2021. H.R. 5169 / S. 2694, Nursing Home Improvement and Accountability Act. H.R. 4445 / S. 2342, Ending Forced Arbitration of Sexual Assault and Sexual Harassment Act of 2021. H.R. 4350, National Defense Authorization Act, with specific regard to amendments on SCRA and USERRA forced arbitration, MCA claims, and cyber incident reporting. H.R.4128, VALID Act of 2021. H.R. 7667, Food and Drug Amendments of 2022, with specific regard to provisions on cosmetics. H.R. 7900, National Defense Authorization Act, with specific regard to amendments on SCRA and USERRA forced arbitration. HR 8227, SPEAK OUT Act. S. 4348, FDA Safety and Landmark Advancements Act. Draft legislation on prohibiting forced arbitration in age discrimination cases. Draft legislation on PFAS. Draft asbestos ban legislation. Draft generic drug labeling legislation. Draft cosmetics reform legislation. Draft dietary supplement legislation. General lobbying on ending the use of forced arbitration for consumers and workers. General lobbying with regard to forced arbitration in nursing homes. General lobbying with regard to COVID-19 liability. General lobbying on e-cigarettes safety and regulation. General lobbying on the FDA proposal regarding the testing of talc for asbestos. General lobbying on FIFRA preemption and Monsanto Company v. Hardeman preemption case. General lobbying on glyphosate safety. General lobbying on drug pricing.
Client expense: $1,010,000 · Firm income: Not reported
Government targets: Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE
2022 · second_quarter · Health Issues
S. 253, Cannabidiol and Marihuana Research Expansion Act, all provisions H.R. 6087, Improving Access to Workers Compensation for Injured Federal Workers Act of 2022, all provisions H.R. 3085, Equity in Neuroscience and Alzheimers Clinical Trials (ENACT) Act of 2021, all provisions H.R. 5030, Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, all provisions H.R. 1384, Mainstreaming Addiction Treatment (MAT) Act of 2021, all provisions S. 445, Mainstreaming Addiction Treatment (MAT) Act of 2021, all provisions H.R. 2067, Medication Access and Training Expansion (MATE) Act of 2021, all provisions S. 2235, Medication Access and Training Expansion (MATE) Act of 2021, all provisions H.R. 6072, Leveraging Integrated Networks in Communities (LINC) To Address Social Needs Act of 2021, provisions relating to social determinants of health, impact on mental health and social services S. 509, Leveraging Integrated Networks in Communities (LINC) To Address Social Needs Act of 2021, provisions relating to social determinants of health, impact on mental health and social services H.R. 379, Improving Social Determinants of Health Act of 2021, all provisions S. 104, Improving Social Determinants of Health Act of 2021, all provisions S. 3799, Prepare for and Respond to Existing Viruses, Emerging New Threats, and (PREVENT) Pandemics Act, all provisions H.R. 8, Bipartisan Background Checks Act of 2021, all provisions H.R. 1446, Enhanced Background Checks Act of 2021, all provisions S. 1675, Maternal Health Quality Improvement Act, all provisions H.R. 2163, Safe Step Act, all provisions S. 464, Safe Step Act, all provisions H.R. 666, Anti-Racism in Public Health Act of 2021, all provisions S. 162, Anti-Racism in Public Health Act of 2021, all provisions H.R. 5248, Temporary Responders for Immediate Aid in Grave Emergencies (TRIAGE) Act of 2021, all provisions H.R. 6311, Comprehensive Addiction Resources Emergency Act of 2021, all provisions S. 3418, Comprehensive Addiction Resources Emergency Act of 2021, all provisions H.R. 1364, Parity Enforcement Act of 2021, all provisions H.R. 3735, Parity Implementation Assistance Act, all provisions H.R. 7232, 9-8-8 and Parity Assistance Act of 2022, all provisions H.R. 7116, 9-8-8 Implementation Act of 2022, all provisions S. 2938, Bipartisan Safer Communities Act, all provisions S. 4090, Dietary Supplement Listing Act of 2022, all provisions S. 1675, Maternal Health Quality Improvement Act, all provisions H.R. 1667, Dr. Lorna Breen Health Care Provider Protection Act, all provisions S. 610, Dr. Lorna Breen Health Care Provider Protection Act, all provisions H.R. 3753, Parity Implementation Assistance Act, all provisions S. 1962, Parity Implementation Assistance Act, all provisions S. 3904, Healthcare Cybersecurity Act of 2022, all provisions H.R. 4128, Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021, all provisions S. 2209, Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021, all provisions H.R. 6000, Cures 2.0 Act, all provisions S. 2416, New Opportunities for Value that Extend Lives (NOVEL) Act of 2021, all provisions H.R. 8152, To provide consumers with foundational data privacy rights, create strong oversight mechanisms, and establish meaningful enforcement, all provisions H.R. 2377, Federal Extreme Risk Protection Order Act of 2022, all provisions H.R. 7910, Protecting Our Kids Act, all provisions S. 2938, Bipartisan Safer Communities Act, all provisions H.R. 7667, Food and Drug Amendments of 2022, all provisions H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022, all provisions H.R. 2503, Social Determinants Accelerator Act of 2021, all provisions S. 3039, Social Determinants Accelerator Act of 2021, all provisions H.R. 7192, Diagnostic Device Advisory Committee Act, all provisions H.R. 3085, Equity in Neuroscience and Alzheimers Clinical Trials (ENACT) Act of 2021, all provisions H.R. 5218, Collaborate in an Orderly and Cohesive Manner Act, all provisions H.R. 7845, NIH Clinical Trial Diversity Act of 2022, all provisions H.R. 708, Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act, all provisions S. 168, Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act, all provisions H.R. 4480, Telehealth Coverage and Payment Parity Act, all provisions H.R. 7573, Telehealth Extension and Evaluation Act, all provisions S. 3593, Telehealth Extension and Evaluation Act, all provisions H.R. 5541, Primary and Virtual Care Affordability Act, all provisions H.R. 1306, National Coronavirus Commission Act of 2021, all provisions S. 412, National Coronavirus Commission Act of 2021, all provisions H.R. 1843, COVID-19 Hate Crimes Act, all provisions S. 937, COVID-19 Hate Crimes Act, all provisions H.R. 3778, Nullifying Opportunities for Variants to Infect and Decimate (NOVID) Act, all provisions S. 1976, Nullifying Opportunities for Variants to Infect and Decimate (NOVID) Act, all provisions H.R. 6904, Patients Before Profits Act of 2022, all provisions H.R. 7053, Hospital Inpatient Services Modernization Act, all provisions S. 3792, Hospital Inpatient Services Modernization Act, all provisions H.R. 1364, Parity Enforcement Act of 2021, all provisions H.R. 5224, Preventing Overdoses and Saving Lives Act of 2021, all provisions H.R. 6279, Opioid Treatment Access Act of 2022, all provisions H.R. 7234, Summer Barrow Prevention, Treatment, and Recovery Act, all provisions H.R. 3352, Midwives for MOMS Act of 2021, all provisions H.R. 847, Promoting Digital Privacy Technologies Act, all provisions S. 224, Promoting Digital Privacy Technologies Act, all provisions H.R. 3771, South Asian Heart Health Awareness and Research Act of 2021, all provisions H.R. 7559, Prescription Information Modernization Act of 2022, all provisions H.R. 8289, Banning Misleading Drug Ads Act of 2022, all provisions H.R. 3614, Menstrual Equity For All Act of 2021, all provisions No Surprises Act/implementation Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act, all provisions 21st Century Cures Act/implementation Maternal mortality Maternal health and inequities/FY 2023 funding Prior Authorization AMA Recovery Plan for Americas Physicians/telehealth/prior authorization/physician burnout/scope Section 2527(b) of the U.S. Innovation and Competition Act (USICA)/Open Access Language Retired Physician Re-entry COVID-19 telehealth flexibilities COVID-19/Vaccine distribution/Vaccines in physician offices Physician burnout and suicide COVID-19/Health Equity/vaccines COVID-19 response/testing/misinformation/therapeutics/Paxlovid Public Health Emergency COVID-19 Health Equity/Men who have sex with men/3-month blood donation use deferral Health Equity/Federally qualified health centers and clinical trials Womens Reproductive Health Medication Abortion Access Diabetes Provider Relief Fund/COVID-19 Electronic Health Records (EHR) Certification Data Privacy Hunger, Nutrition, and Health Digital Health/AI/Digital Therapeutics Monkeypox/testing/vaccination
Client expense: $4,550,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), President of the U.S., SENATE, Vice President of the U.S., White House Office
2022 · fourth_quarter · Health Issues
VALID Act (HR 4128/S.2209); General Issues related to data privacy and security.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
Diagnostics coverage and reimbursement. H.R.4128 - VALID Act of 2021.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
H.R.8295/S.4659, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2023, Laboratory infrastructure; Mental Health initiatives H.R.4128/S.2209, Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021, generally S.4348, Food and Drug Administration Safety and Landmark Advancements Act, Lab Develop Testing issues Public Law 117-328, Consolidated Appropriations Act, FY2023, Laboratory infrastructure; Diagnostic Laboratory Testing issues Monitor the following: H.R.7667, Food and Drug Amendments Act, Lab Develop Testing issues Mental Health initiatives Center for Excellence in Improving Diagnosis legislation 340B generally P.L.117-2, American Rescue Plan Act of 2021, Hospital and healthcare funding eligibility related issues Surprise Billing Health Care Transparency Prescription Drug Cost Disproportionate Share Hospital (DSH) Coronavirus, Hospital and Healthcare Telehealth initiatives H.R.6000, CURES 2.0, Health services delivery; and Research and development issues ARPA-H Proposal Public Law 117-169, Inflation Reduction Act of 2022, Implementation issues
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Medical/Disease Research/Clinical Labs
Antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR Act-S. 2076/H.R. 3932), Verifying Accurate Leading Edge IVCT Development (S. 2209/HR. 4128), PREVENT Pandemics Act
Client expense: $166,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2022 · second_quarter · Medical/Disease Research/Clinical Labs
2023 appropriations requests for NIH for T cell research in COVID19 and other disease areas; HR4128 and S2209 The VALID Act. Provisions related to first of a kind assays
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Medical/Disease Research/Clinical Labs
HR2471 Appropriations for NIH for T cell research in COVID19 and other disease areas; HR4128 and S2209 The VALID Act. Provisions related to first of a kind assays
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
-Support provisions of Cures 2.0 legislation (HR 6000) -Support provisions of VALID Act (HR 4128/S 2209) -Support FDASLA (S 4348) -Support ARPA-H legislation -Oppose limiting telehealth lab orders
Client expense: $480,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Medicare/Medicaid
S.510 - Protecting Medicare and American Farmers from Sequester Cuts Act of 2021 HR 8702 & S 5007 - the Holding Providers Harmless From Medicare Cuts During COVID-19 Act of 2020 HR 3502 - Protecting People from Surprise Medical Bills Act HR 3630 - to amend title XXVII of the Public Health Service Act S 1370 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 HR4128 - Verifying Accurate Leading Edge IVCT Development (VALID) Act of 2021 Prostate Cancer Misdiagnosis Elimination Act Resident Physician Shortage Reduction Act of 2019, S 348, HR 1763 HR8800 - Supporting Medicare Providers Act HR3173/S3018 - Improving Seniors' Timely Access to Care Act HR8188- Saving Access to Laboratory Services Act
Client expense: $111,309 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
Legislation and policies relating to: Adoption of recommendations of the National Academy of Medicine report, The Future of Nursing 2020-2030: Charting a Path to Achieve Health Equity Provisions of the Patient Protection & Affordable Care Act (P.L. 111-148) Reauthorization of the Childrens Health Insurance Program Reauthorization of the Child Nutrition Act Section 2706 of the ACA regarding provider non-discrimination Policies affecting nurse practitioner education and workforce Definition, evaluation and enforcement of essential health benefits and provider network adequacy Health information technology and electronic health records Mental health services and violence prevention H.R. 66, Comprehensive Access to Robust Insurance Now Guaranteed for Kids (CARING for Kids) Act H.R. 482/S. 350, Newborn Screening Saves Lives Reauthorization Act of 2021 H.R. 485, Stronger Child Abuse Prevention and Treatment Act H.R. 550, Immunization Infrastructure Modernization Act of 2021 H.R. 909/S. 484, Moms Matter Act H.R. 959/S. 346, Black Maternal Health Momnibus Act of 2021 H.R. 1065/S. 1486, Pregnant Workers Fairness Act H.R. 1324/S/ 467, Effective Suicide Screening and Assessment in the Emergency Department Act of 2021 H.R. 1390, Childrens Health Insurance Program Pandemic Enhancement and Relief (CHIPPER) Act H.R. 1620, Violence Against Women Act Reauthorization Act of 2021 H.R. 1791, Childrens Health Insurance Program Permanency (CHIPP) Act H.R. 2094/S. 1301, Promoting Physical Activity for Americans Act H.R. 2347/S. 2691, Strengthening the Vaccines for Children Program Act of 2021 H.R. 3173/S. 3018, Improving Seniors Timely Access to Care Act of 2021 H.R. 3182, Safe Sleep for Babies Act of 2021 H.R. 3407/S. 411, Mothers and Offspring Mortality and Morbidity Awareness (MOMMAs) Act H.R. 3655, Vaccine Injury Compensation Modernization Act of 2021 H.R. 4128/S. 2209, Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 H.R. 4217/S. 2779, Taskforce Recommending Improvements for Unaddressed Mental Perinatal & Postpartum Health (TRIUMPH) for New Moms Act Implementation of the Inflation Reduction Act (P.L. 117-169) provisions related to health equity and mental and behavioral health for patients and health care providers H.R. 5487/S. 3972, Stillbirth Health Improvement and Education (SHINE) for Autumn Act of 2021 H.R. 7076, Supporting Childrens Mental Health Care Access Act of 2022 H.R. 7236, Strengthen Kids Mental Health Now Act of 2022 H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022 H.R. 7780, Mental Health Matters Act H.R. 8296, Womens Health Protection Act of 2022 H.R. 8391, Continuity in Necessary Evaluative Crisis Treatment (CONNECT) Act of 2022 H.R. 8450, Healthy Meals, Healthy Kids Act H.R. 8812/S. 5212, Improving Care and Access to Nurses (I CAN) Act H.R. 8817/S. 4844, National Nursing Workforce Centers Act H.R. 9260, Stop Online Suicide Assistance Forums Act S. 104/H.R. 379, Improving Social Determinants of Health Act of 2021 S. 248/H.R. 804, Family and Medical Insurance Leave (FAMILY) Act S. 499/H.R. 369, Improving Health Insurance Affordability Act of 2021 S. 674, Public Health Infrastructure Saves Lives Act S. 844/H.R. 3109, PHIT Act of 2021 S. 1259, Safe Cribs Act S. 1275/H.R. 2119, Family Violence Prevention and Services Improvement Act of 2021 S. 1658/H.R. 3110, Providing Urgent Maternal Protections (PUMP) for Nursing Mothers Act S. 1675/H.R. 4387, Maternal Health Quality Improvement Act S. 2069/H.R. 4323, Excellence in Mental Health and Addiction Treatment Act S. 3479/H.R. 8151, Building a Sustainable Workforce for Healthy Communities Act S. 3623, Violence Against Women Act Reauthorization Act of 2022 S. 3799, Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act (PREVENT Pandemics Act) S. 4170, Mental Health Reform Reauthorization Act of 2022 S. 4472, Health Care Capacity for Pediatric Mental Health Act of 2022
Client expense: Not reported · Firm income: $24,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · fourth_quarter · Health Issues
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-328 (H.R. 2617): Consolidated Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
Client expense: $1,300,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Budget/Appropriations
HR. 4128, VALID Act of 2021 and H.R. 2617, 2023 Consolidated Appropriations Act; specifically, provisions related to veteran programs and associated funding.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
2022 · fourth_quarter · Veterans
HR. 4128, VALID Act of 2021 and H.R. 2617, 2023 Consolidated Appropriations Act; specifically, provisions related to veteran programs and associated funding.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
2022 · fourth_quarter · Medical/Disease Research/Clinical Labs
H.R. 4128/S. 2209, The Verifying Leading-edge IVCT Development Act of 2021.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
H.R. 4128/S. 2209, The Verifying Leading-edge IVCT Development Act of 2021.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Medical/Disease Research/Clinical Labs
Ensuring access to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing, The VALID Act HR 4128 and S 2209; Use of real-world evidence in clinical trials and FDA review. White House Cancer Moonshot Initiative; HR 2617 Consolidated Appropriations Act of 2023
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
VALID Act of 2021 (H.R. 4128/S. 2209) Provisions related to the regulation of laboratory-developed tests (LDTs) in academic clinical laboratories FDASLA Act of 2022 (S. 4348) Provisions related to the regulation of laboratory-developed tests (LDTs) in academic clinical laboratories
Client expense: $120,000 · Firm income: Not reported
Government targets: SENATE
2022 · fourth_quarter · Health Issues
Congressional Personalized Medicine Caucus H.R. 5989 Precision Medicine Answers for Kids Today Act H.R. 6000 Cures 2.0 H.R. 6875 Right Drug Dose Now Act H.R. 4128/S.2209 The VALID Act of 2021 H.R. 2144/S. 1450 Access to Genetic Counselors Services Act H.R. 5376 Inflation Reduction Act of 2022 Food and Drug Omnibus Reform Act of 2022 Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $38,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Medical/Disease Research/Clinical Labs
Sickle cell disease/trait issues Hematology/oncology treatment issues Hematology/oncology drug research and approval issues General hematology public health and research issues Emergency funding for COVID therapeutics Research Investment to Spark the Economy (RISE) Act (H.R. 869/S. 289) Open access policy for peer reviewed research journals Issues impacting blood supply shortages/safety Issues related to convalescent plasma Issues impacting delivery of bone marrow, peripheral blood, and cord blood Issues related to implementation of Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136) Issues related to health equity/disproportionate impact of COVID-19 on minority populations COVID-19 vaccination policies/prioritization Clinical trials regulations and coverage Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training Cures 2.0 Act (H.R. 6000) Advanced Research Projects Agency for Health (ARPA-H) Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act (S. 2706 / H.R. 5030) Meaningful Access to Federal Health Plan Claims Data Act (H.R. 5394) Health Equity and Accountability Act (H.R. 7585) Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 4128/S. 2209) Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348)
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), President of the U.S., SENATE
2022 · fourth_quarter · Health Issues
Resident Physician Shortage Reduction Act (H.R. 2256/S. 834) Healthcare Workforce Resilience Act (H.R. 2255/S. 1024) Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting opioid access/use for patients with hematologic disease and disorders Issues impacting blood supply shortages/safety Issues related to convalescent plasma Issues related to health equity/disproportionate impact of COVID-19 on minority populations Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training Cures 2.0 Act (H.R. 6000) Implementation of No Surprises Act (P.L. 116-260) Cancer Patient Equity Act of 2021 (H.R.5377) HELP Copays Act (H.R. 5801) Cancer Drug Parity Act of 2021 (H.R. 4385 / S. 3080) Sickle cell disease/trait issues Sickle Cell Disease Comprehensive Care Act (H.R. 6216 / S.3389) Impact of climate change on health Resolution expressing support for healthcare personnel and condemning assaults on healthcare personnel as the U.S. healthcare system faces unprecedented staffing shortages and increased workplace-related stressors (H.Res. 909) Sickle Cell Care Expansion Act (H.R. 7177/S.4425) Women's Health Protection Act (S. 1975/ H.R. 3755/S. 4132) Newborn Screening Saves Lives Reauthorization Act (H.R. 482/S. 350) Prior authorization Improving Seniors Timely Access to Care Act (H.R. 3173/S. 3018) Health Equity and Accountability Act (H.R. 7585) Issues related to maternal health care and abortion access Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 4128/S. 2209) Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348) Affordability of employer coverage for family members/"family glitch Sickle Cell Disease Treatment Centers Act of 2022 (S. 4866/ H.R. 8855) Advancing Telehealth Beyond COVID Act (H.R. 4040) Resolution supporting the designation of September 2022 as "Sickle Cell Disease Awareness Month" (H.Res.1330/S.Res.868) Let Doctors Provide Reproductive Health Care Act (S. 4723/H.R. 8650) FY2023 Consolidated Appropriations Act (H.R. 2617)
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Natl Institutes of Health (NIH), SENATE
2022 · fourth_quarter · Health Issues
Issues related to public research universities and the hospitals they operate. VALID Act of 2021 (H.R. 4128/S. 2209); Telehealth waivers for Medicare payments
Client expense: $178,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Natl Science Foundation (NSF), Office of Science & Technology Policy (OSTP), SENATE
2022 · fourth_quarter · Health Issues
VALID Act of 2021 (HR 4128/S.2209); Issues related to proposals on reauthorization of the FDA drug and device user fee programs within Omnibus Bill (H.R. 2617 ); Issues related to data privacy and security House legislation (H.R. 8152).
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Medical/Disease Research/Clinical Labs
Access and reimbursement to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing; The VALID Act (HR 4128 and S 2209) and Omnibus legislation (H.R. 2617). Increasing overall access to and diversity of clinical trials. Advancing acceptance of Real World Data and Real World Evidence.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
Issue: Educate Congress and the administration on academic medicines missions, including education, research, patient care, GME, workforce, and physician shortages in rural and urban communities. Draft Graduate Medical Education Reform Act Issue: Support increased funding for the National Health Service Corps, Teaching Health Center GME, and National Disaster Medical Service (NDMS) demonstration pilot. Support increased Medicare support for Graduate Medical Education/physician training. Issues: Educate Congress and the administration about the role of academic medicine in the provision of mental and behavioral health care, including initiatives to respond to the opioid epidemic. Support measures to expand access to mental health care and substance use disorder treatment, including funding for training on substance use disorders, pain management, and safe prescribing practices, enhance enforcement of mental health parity laws, increased financial support for integrated behavioral health models. Support the provision of additional Medicare-supported graduate medical education slots for psychiatry and psychiatry sub-specialties. P.L. 117-328, Consolidated Appropriations Act, 2023 Support the provision of 200 additional Medicare-supported graduate medical education (GME) positions. Support the extension of COVID-related telehealth flexibilities. Support elimination or delay of Statutory Pay-As-You-Go (PAYGO) Medicare sequester and eliminating or reducing scheduled cuts to the Physician Fee Schedule. Support one-year of continuous Medicaid coverage for children. Support extension of postpartum Medicaid and CHIP coverage for 12 months. H.R. 1384/ S.445, Mainstreaming Addiction Treatment (MAT) Act of 2021 P.L. 117-328, Consolidated Appropriations Act, 2023, Division FF Issue: Support suspension of waiver requirement for certain providers to prescribe buprenorphine. H.R. 2067, Medication Access and Training Expansion (MATE) Act of 2021 P.L. 117-328, Consolidated Appropriations Act, 2023, Division FF Issue: Oppose legislative mandates dictating medical education curriculum on pain management and addiction. H.R. 7236, Strengthen Kids Mental Health Now Act/ S. 2727 Investing in Kids Mental Health Now Act Issue: Support increasing Medicaid reimbursement rates for pediatric mental health services through a 100% federal match. P.L. 116-22, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 Issues: Support the Hospital Preparedness Program and the reauthorization of the Pandemic and All-Hazards Preparedness Act. Support increased funding authorization levels. Issue: Educate Congress on how the 340B Drug Pricing Program helps safety-net providers to fulfill their missions and care for patients and communities. Support measures to preserve and strengthen the 340B Drug Pricing Program and oppose efforts to reduce the scope of the program, including restrictions on covered entities use of contract pharmacy to distribute covered drugs. H.R. 4390, Preserving Rules Ordered for the Entities Covered Through 340B Act of 2021 (PROTECT 340B Act) Issue: Support measures to prevent pharmacy benefit managers and commercial insurers from discriminating against 340B covered entities. H.R. 3203/S. 773 Issue: Support policy to allow 340B DSH hospitals to remain eligible to participate in the program throughout the current public health emergency even if their DSH adjustment falls below the current threshold due to changes in payer mix as a result of the COVID-19 pandemic. Issue: Oppose insurance plans that do not meet Affordable Care Act requirements. Issue: Support increased interoperability and exchange of electronic health information and delayed enforcement of information blocking rule until comprehensive guidance is issued. Issue: Support the ongoing refinement of the two new mandatory alternative payment models, the Radiation Oncology Model and End-stage Renal Disease Treatment Choices Model, to better incentivize high-quality care for all patients. H.R. 4128/ S. 2209, Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022 P.L. 117-328, Consolidated Appropriations Act, 2023 Issue: Educate Congress on development of Laboratory Developed Tests at academic medical centers and oppose policies that would increase burdensome regulations and negatively impact patients access to care by allowing Food and Drug Administration regulation of the development of Laboratory Developed Tests at academic medical centers. S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022 H.R. 7667, Food and Drug Amendments of 2022 (FDA22) P.L. 117-328, Consolidated Appropriations Act, 2023 Issue: Support promotion of data sharing and clinical trials results reporting. Support increased clinical trials diversity. Issue: Development of Enhanced Primary Care Pilot Act proposal H.R. 2503 / S. 3039, Social Determinants Accelerator Act of 2021 Issue: Support grants to address social determinants of health H.R. 7585 / S. 4486, Health Equity and Accountability Act Issue: Support programs to improve health equity and address social determinants of health. Issue: Support incentives to encourage the inclusion of implicit bias training in medical education and residency training. Issue: Support congressional investment in the Centers for Medicare and Medicaid Innovation (CMMI) models to reduce maternal mortality and improve maternal health. Issue: Support maternal health initiatives to expand coverage during the postpartum period and expand demonstration project grants. H.R. 959, Black Maternal Health Momnibus Act of 2021 S. 1695 / H.R. 4387, Maternal Health Quality Improvement Act S. 1491/ H.R. 769, Rural MOMs Act H.R. 4387, Maternal Health Quality Improvement Act of 2021 H.R. 925 / S. 347, Data to Save Moms Act Issue: Support legislative efforts to improve maternal health and reduce rates of maternal mortality, including the Momnibus. Support legislative initiatives to improve data collection to improve maternal health equity. P.L. 117-159, Bipartisan Safer Communities Act Issue: Support policies to promote firearm safety, universal background checks, violence prevention programs, extreme risk protection orders, child access safety laws, reinstating assault weapons ban, data infrastructure, hospital based and community violence intervention programs, and programs to address mental and behavioral health impact of gun violence. Issue: Support funding for Community Violence Interventions / Hospital Based Violence Intervention Programs P.L. 117-105, Dr. Lorna Breen Health Care Provider Protection Act Issue: Support grants directed at improving clinician burnout and well-being. Issue: Provide feedback on implementation of the Provider Relief Fund. Support extension for use of PRF funds. Issue: Support improvements to the Medicare Accelerated and Advance Payment Programs, including delaying recoupment of MAAP loans. Issue: Support extension of public health emergency declaration. Issue: Provide feedback on COVID-19 and pandemic response. Provide feedback on monkeypox response including testing. S. 3799, PREVENT Pandemics Act P.L. 117-328, Consolidated Appropriations Act, 2023, Division FF Issue: Provide feedback on pandemic preparedness legislation, urge inclusion of provisions to support academic medical centers preparedness activities. Issue: Support establishment of regional pandemic response centers, stronger linkages between public health and academic medicine, and the role of medical students and academic medical centers in administering COVID vaccines. Issue: Support efforts of academic medical centers to respond to public health threats such as monkeypox and COVID-19. Urge establishment and implementation of robust national testing strategy; functional, redundant, and transparent supply chain; improved federal coordination; investments in public health and health care human and other resources; data modernization initiatives; and other actions to improve current and future pandemic response. H.R. 708, S. 168, Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act Issue: Support for a temporary uniform licensing standard for all practitioners in all states throughout the COVID-19 public health emergency S. 674 Public Health Infrastructure Saves Lives Act Issue: Support investments in core public health infrastructure. Issue: Support ensuring patients are put first, that conscience protections align with medical professionalism standards, and oppose interference in the patient-physician relationship. Issue: Support increased interoperability and exchange of electronic health information. Support delay of enforcement beyond April 2021. H.R. 6000, Cures 2.0 Act Issue: Provide feedback on provisions related to public health, patients and caregivers, FDA, CMS, and research, and ARPA-H. Issue: Promote strategies to strengthen the health, public health, and research workforces. H.R. 3671, Doctors of Community Act Issue: Discuss authorization of the Teaching Health Center Graduate Medical Education program. H.R. 8131, Increasing Competition for Medical Residency Act Issue: Educate Congress on the medical education and training continuum, the annual residency Match, and the role of the National Resident Matching Program (NRMP) in medical education and residency. Issue: Provide guidance on the implementation of the No Surprises Act. Issue: Provide feedback on proposed modifications to the HIPAA privacy rule. H.R. 5035 / S. 2982, Child Suicide Prevention and Lethal Means Safety Act Issue: Support legislation to provide grants to improve suicide prevention and lethal means safety. Issue: Inform Congress and Administration about medical education on caring for older adults, nutrition, climate change, stigma around addiction, reproductive health, and accelerated medical education training programs. Issue: Provide feedback on efforts of the academic medicine community to address climate change and decarbonization. Issue: Support efforts of teaching hospitals to promote patient safety and high-quality care. H.R. 7152/ S.3534, The Tracking Pathogens Act P.L. 117-328, Consolidated Appropriations Act, 2023, Division FF Issue: Support expansion of CDC activities related to genomic sequencing of pathogens. Issue: Support reignition of Cancer Moonshot. H.R. 7961, Safety from Violence for Healthcare Employees (SAVE) Act Issue: Support statutory protections against violence and intimidation for health care workers and provide grants for hospital programs aimed at preventing violence in health care settings. P.L. 117-263, James M. Inhofe National Defense Authorization Act for Fiscal Year 2023 Issue: Support a one year pause in military medical billet reductions in the Military Health System.
Client expense: $876,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), Office of Science & Technology Policy (OSTP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Vice President of the U.S., White House Office
2022 · fourth_quarter · Health Issues
Support increased funding for the USPSTF and H.R. 9310, Preventative Services Early Action Act. Monitor S. 2209/H.R. 4128 VALID Act and FY 23 Labor-HHS appropriations.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE